Abdullah, Wahida B.
HRN: 21-29-91 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/06/2022
CO-AMOXICLAV 625MG (TAB)
05/06/2022
05/12/2022
PO
625mg
BID
S/P CS
Waiting Final Action
Indication: Prophylaxis Type of Infection: BloodstreamSkin & Soft TissueIntra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes